Tamara Joseph was Appointed as General Counsel at Enzyvant

Date of management change: June 04, 2018 

What Happened?

Cambridge, -based Enzyvant Appointed Tamara Joseph as General Counsel

 

About the Company

Enzyvant is also advancing the development of RVT-802, an investigational tissue-based biologic therapy for the potential treatment of primary immune deficiency associated with complete DiGeorge Syndrome. RVT-802 has been granted orphan drug designation, Breakthrough Therapy designation, Regenerative Medicine Advanced Therapy designation, and pediatric rare disease designation by the U.S. Food and Drug Administration. Enzyvant anticipates a potential BLA filing for RVT-802 in the first half of 2018. Enzyvant plans to develop treatments for additional rare diseases with high unmet need.

 

About the Person

Tamara Joseph is General Counsel at Enzyvant. Previously, Tamara held various senior legal leadership roles in the industry.

 

Info Source

News

 
 

Other IT executives who recently changed jobs as well: Jacobs Lawrence, Rak Andrew, Farwell Ellen, Franken Anthony, Thunhorst Wade, Zuchowski Lynn, Felder Cole, Hulett Skip, Callahan Timothy, Haugh Lisa, Jagger David

You can find the full directory of IT executives here.

How would you like to connect with 15,000+ IT executives in charge of $ millions in IT budgets? Find details here.